Ardelyx, Inc. (ARDX) stock
ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3060% below fair value
$2.99−0.07 (-2.29%)
Close on Nov 20, 2026Market cap $745.07MP/E –Yield –
Ardelyx gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Ardelyx's gross profit for the twelve months ending Jun 30, 2026 was $425.49M, up 29.9% year over year. For fiscal 2025 it was $367.78M, up 29.9% from the year before. The highest annual figure on record is $367.78M in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $367.78M | +29.9% |
| FY2024 | Dec 31, 2024 | $283.06M | +165.4% |
| FY2023 | Dec 31, 2023 | $106.66M | +122.0% |
| FY2022 | Dec 31, 2022 | $48.04M | +428.1% |
| FY2021 | Dec 31, 2021 | $9.10M | +22.5% |
| FY2020 | Dec 31, 2020 | $7.43M | +58.6% |
| FY2019 | Dec 31, 2019 | $4.68M | +118.6% |
| FY2018 | Dec 31, 2018 | $2.14M | -93.6% |
| FY2017 | Dec 31, 2017 | $33.60M | +39.8% |
| FY2015 | Dec 31, 2015 | $24.03M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $115.12M | +35.0% |
| Q1 FY2026 | Mar 31, 2026 | $89.66M | +45.1% |
| Q4 FY2025 | Dec 31, 2025 | $114.37M | +16.9% |
| Q3 FY2025 | Sep 30, 2025 | $106.35M | +28.9% |
| Q2 FY2025 | Jun 30, 2025 | $85.26M | +33.7% |
| Q1 FY2025 | Mar 31, 2025 | $61.81M | +58.9% |
| Q4 FY2024 | Dec 31, 2024 | $97.87M | +234.2% |
| Q3 FY2024 | Sep 30, 2024 | $82.51M | +69.4% |
| Q2 FY2024 | Jun 30, 2024 | $63.79M | +238.5% |
| Q1 FY2024 | Mar 31, 2024 | $38.90M | +295.6% |
| Q4 FY2023 | Dec 31, 2023 | $29.29M | -28.6% |
| Q3 FY2023 | Sep 30, 2023 | $48.70M | +1044.8% |
| Q2 FY2023 | Jun 30, 2023 | $18.84M | +689.1% |
| Q1 FY2023 | Mar 31, 2023 | $9.83M | +2467.1% |
| Q4 FY2022 | Dec 31, 2022 | $41.02M | +3886.0% |
| Q3 FY2022 | Sep 30, 2022 | $4.25M | +262.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.39M | +81.9% |
| Q1 FY2022 | Mar 31, 2022 | $383.00K | -93.1% |
| Q4 FY2021 | Dec 31, 2021 | $1.03M | -43.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.17M | -56.8% |
| Q2 FY2021 | Jun 30, 2021 | $1.31M | -22.5% |
| Q1 FY2021 | Mar 31, 2021 | $5.58M | +360.2% |
| Q4 FY2020 | Dec 31, 2020 | $1.81M | -19.8% |
| Q3 FY2020 | Sep 30, 2020 | $2.71M | +12.4% |
| Q2 FY2020 | Jun 30, 2020 | $1.70M | +9316.7% |
| Q1 FY2020 | Mar 31, 2020 | $1.21M | +1327.1% |
| Q4 FY2019 | Dec 31, 2019 | $2.25M | +1223.5% |
| Q3 FY2019 | Sep 30, 2019 | $2.41M | +7943.3% |
| Q2 FY2019 | Jun 30, 2019 | $18.00K | -99.0% |
| Q4 FY2018 | Dec 31, 2018 | $85.00K | -99.7% |
| Q3 FY2018 | Sep 30, 2018 | $170.00K | – |
| Q2 FY2018 | Jun 30, 2018 | $30.00K | – |
| Q1 FY2018 | Mar 31, 2018 | $1.86M | – |
| Q4 FY2017 | Dec 31, 2017 | $33.60M | – |
See a number that looks wrong?